333 related articles for article (PubMed ID: 37416927)
1. Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma.
Jiang W; Wei Q; Xie H; Wu D; He H; Lv X
Anal Cell Pathol (Amst); 2023; 2023():4522045. PubMed ID: 37416927
[TBL] [Abstract][Full Text] [Related]
2. High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.
Gao P; Zou K; Xiao L; Zhou H; Xu X; Zeng Z; Zhang W
Int Immunopharmacol; 2022 Sep; 110():108954. PubMed ID: 35820363
[TBL] [Abstract][Full Text] [Related]
3. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma.
Hou Y; Xiang B; Yang Z; Liu J; Xu D; Geng L; Zhan M; Xu Y; Zhang B
Int J Immunopathol Pharmacol; 2023; 37():3946320231202748. PubMed ID: 37731383
[No Abstract] [Full Text] [Related]
5. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
6. High Expression of
Deng H; Huang Y; Wang L; Chen M
Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
[TBL] [Abstract][Full Text] [Related]
7. The EMT-Related Genes GALNT3 and OAS1 are Associated with Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma.
Luo D; Fang M; Shao L; Wang J; Liang Y; Chen M; Gui X; Yan J; Wang W; Yu L; Fan X; Wu Q
Front Biosci (Landmark Ed); 2023 Oct; 28(10):271. PubMed ID: 37919050
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
9. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
10. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
11. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L
Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642
[TBL] [Abstract][Full Text] [Related]
12. Junctional Adhesion Molecule-Like Protein (JAML) Is Correlated with Prognosis and Immune Infiltrates in Lung Adenocarcinoma.
Fang L; Yu W; Yu G; Zhong F; Ye B
Med Sci Monit; 2022 Jan; 28():e933503. PubMed ID: 35034089
[TBL] [Abstract][Full Text] [Related]
13. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
14. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target.
Chen M; Zhang S; Wang F; He J; Jiang W; Zhang L
J Transl Med; 2024 Feb; 22(1):209. PubMed ID: 38414025
[TBL] [Abstract][Full Text] [Related]
15. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
[TBL] [Abstract][Full Text] [Related]
16. PHD3 as a Prognosis Marker and its Relationship with Immune Infiltration in Lung Adenocarcinoma.
Wang L; Zhong Y; Wang G; An H; Gao Q; Ye Y
Comb Chem High Throughput Screen; 2022; 25(13):2255-2263. PubMed ID: 35088661
[TBL] [Abstract][Full Text] [Related]
17. DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma.
Wu YJ; Nai AT; He GC; Xiao F; Li ZM; Tang SY; Liu YP; Ai XH
World J Surg Oncol; 2021 Sep; 19(1):274. PubMed ID: 34517904
[TBL] [Abstract][Full Text] [Related]
18. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
[TBL] [Abstract][Full Text] [Related]
19. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
20. Independent Prognostic Potential of GNPNAT1 in Lung Adenocarcinoma.
Zheng X; Li Y; Ma C; Zhang J; Zhang Y; Fu Z; Luo H
Biomed Res Int; 2020; 2020():8851437. PubMed ID: 33178836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
